Table 1.
Patients’ characteristics.
| Characteristics | Patient number (%), N=6 |
|---|---|
| Age, median (range) | 68 (57-71) |
| Sex | |
| Male | 3 (50) |
| Female | 3 (50) |
| Race | |
| White | 3 (50) |
| Black | 2 (33) |
| Asian | 1 (17) |
| Diagnosis | |
| Acute myeloid leukemia | 3 (50) |
| Myelodysplastic syndrome | 2 (33) |
| Primary myelofibrosis | 1 (17) |
| Disease status at transplantation | |
| CR1 | 1 (17) |
| Active disease | 2 (33) |
| Stable disease | 3 (50) |
| HCT-CI | |
| 1 to 2 | 3 (50) |
| 3 or more | 3 (50) |
| CB TNC dose, median (range), x107/kg | 3.2 (1.9-7.1) |
| CB CD34+ dose, median (range), x106/kg | 0.12 (0.03-0.37) |
| Conditioning regimen | |
| Flu/Cy/TBI | 4 (67) |
| Flu/Mel/ATG | 2 (33) |
| Karnofsky performance status, % | |
| 70 | 3 (50) |
| 80 | 3 (50) |
| HLA match | |
| 5/6 | 4 (67) |
| 6/6 | 2 (33) |
| GvHD prophylaxis | |
| MMF + Cyclosporin | 4 (67) |
| MMF + Tacrolimus | 2 (33) |
CR, complete remission; HCT-CI, hematopoietic cell transplantation-specific comorbidity index; CB, cord blood; TNC, total nucleated cell; Flu, fludarabine; Cy, cyclophosphamide; TBI, total body irradiation; Mel, melphalan; ATG, antithymocyte globulin; GvHD, graft-versus-host disease; MMF, mycophenolate mofetil.